Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factorAnaïs Schavgoulidze, Jill Corre, Sabrina Mahéo et al.|Blood|2022Cited by 64
Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periodsJill Corre, Aurore Perrot, Cyrille Hulin et al.|Leukemia|2021Cited by 41
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical featuresTitouan Cazaubiel, Jill Corre, Xavier Leleu et al.|Blood|2022Cited by 30
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experiencePhilippe Moreau, Aurore Perrot, Cyrille Hulin et al.|Blood Cancer Journal|2025Cited by 2